IP Library Granted Patent US 12,060,430
Granted Patent B2
US 12,060,430 · App. 17/332,578 · Granted Aug 13, 2024

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

Inventors: Junming Yie (Warren, NJ); Donghui Shi (Thousand Oaks, CA); David J. Lloyd (Thousand Oaks, CA); Jinghong Wang (Palo Alto, CA); Glenn N. Sivits, Jr. (Newbury Park, CA); Murielle M. Veniant-Ellison (Thousand Oaks, CA); Renee Komorowski (Ventura, CA); Neeraj Agrawal (Thousand Oaks, CA); Darren L. Bates (Oak Park, CA); Brandon C. P. Clavette (Coquitlam, CA); Ian N. Foltz (Burnaby, CA); Shu-yin Ho (Thousand Oaks, CA); Christopher Murawsky (Roberts Creek, CA); Xiaoshan Min (Burlingame, CA); Zhulun Wang (Palo Alto, CA)
Assignee: Amgen Inc.
C07K16/2869A61K9/0019A61K38/1703A61K38/26A61K39/3955A61K2039/505A61K2039/54C07K2299/00C07K2317/21C07K2317/32C07K2317/33C07K2317/41C07K2317/52C07K2317/71C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,060,430
App. No.
17/332,578
Granted
Aug 13, 2024
Kind
B2
Abstract

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Claims (8)

1. A nucleic acid molecule encoding an antibody selected from the group consisting of:

a) an antibody comprising a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein said CDRL1 comprises SEQ ID NO: 702; said CDRL2 comprises SEQ ID NO: 859; said CDRL3 comprises SEQ ID NO: 1016; said CDRH1 comprises SEQ ID NO: 1173; said CDRH2 comprises SEQ ID NO: 1330; and said CDRH3 comprises SEQ ID NO: 1487;

b) an antibody comprising a light chain variable region comprising SEQ ID NO: 74 and a heavy chain variable region comprising SEQ ID NO: 231; and

c) an antibody comprising a light chain comprising SEQ ID NO: 388 and a heavy chain comprising SEQ ID NO: 545.

2. The nucleic acid molecule according to claim 1 , wherein said nucleic acid molecule is operably linked to a control sequence.

3. A vector comprising a nucleic acid molecule according to claim 2 .

4. A host cell comprising the nucleic acid molecule according to claim 3 .

5. A method of making the antibody the antibody, comprising the step of preparing said antibody said antibody from a host cell of claim 4 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2022
From: YIE, JUMMING; SHI, DONGHUI; LLOYD, DAVID J.; WANG, JINGHONG; SIVITS, GLENN N., JR.; VENIANT-ELLISON, MURIELLE M.; KOMOROWSKI, RENEE; AGRAWAL, NEERAJ; BATES, DARREN L; CLAVETTE, BRANDON C. P.; FOLTZ, IAN N.; HO, SHU-YIN; MURAWSKY, CHRISTOPHER; MIN, XIAOSHAN; WANG, ZHULUN
To: AMGEN INC.
Reel/Frame 061334/0365 →
Continuity (6)
Division 16285118 · Feb 25, 2019
Division 15387542 · Dec 21, 2016
Provisional Application 62420415 · Nov 10, 2016
Provisional Application 62337799 · May 17, 2016
Provisional Application 62387486 · Dec 23, 2015
Related Publication 20220025059A1 · Jan 27, 2022